Intra-Cellular Therapies ... (ITCI)
131.70
0.00 (0.00%)
At close: Mar 25, 2025, 3:59 PM
131.74
0.03%
After-hours: Mar 25, 2025, 06:28 PM EDT
Intra-Cellular Therapies Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Revenue | 680.85M | 464.37M | 249.13M | 81.71M | 22.53M | 60.61K | n/a | 245.84K | 330.7K | 91.36K | 577.3K | 2.74M | 3.12M |
| Cost of Revenue | 56.96M | 33.74M | 20.44M | 8.03M | 1.9M | 477.12K | 368.67K | 79.42M | 93.83M | 139.63K | 21.23M | 23.03M | 15.49M |
| Gross Profit | 623.89M | 430.63M | 228.69M | 73.67M | 20.64M | -416.51K | -368.67K | -79.17M | -93.5M | -48.26K | -20.65M | -20.29M | -12.37M |
| Operating Income | -116.72M | -159.38M | -263.63M | -285.69M | -231.23M | -154.01M | -162.27M | -102.84M | -118.26M | -105.81M | -30.99M | -26.27M | -16.4M |
| Interest Income | 42.52M | 20.34M | 7.38M | 1.57M | 4.24M | 6.29M | 7.14M | 4.01M | 2.94M | 1.02M | 303.94K | 29.62K | 39K |
| Pretax Income | -74.2M | -139.04M | -256.25M | -284.12M | -226.99M | -147.72M | -155.13M | -98.83M | -115.36M | -104.79M | -30.69M | -26.85M | -16.56M |
| Net Income | -74.68M | -139.67M | -256.26M | -284.13M | -227.01M | -147.72M | -155.13M | -97.77M | -116.43M | -104.79M | -30.69M | -26.87M | -16.59M |
| Selling & General & Admin | 504.49M | 409.86M | 358.78M | 272.61M | 186.36M | 64.95M | 30.1M | 23.67M | 24.76M | 18.19M | 10.34M | 5.98M | 4.03M |
| Research & Development | 236.12M | 180.14M | 134.72M | 88.85M | 65.78M | 89.12M | 132.17M | 79.42M | 93.83M | 87.72M | 21.23M | 23.03M | 15.49M |
| Other Expenses | n/a | n/a | -1.18M | -2.1M | -282.23K | n/a | n/a | -245.84K | -330.7K | -60.7K | -29.75K | n/a | n/a |
| Operating Expenses | 740.61M | 590.01M | 492.31M | 359.36M | 251.86M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29M | 19.52M |
| Interest Expense | n/a | n/a | 7.38M | n/a | n/a | n/a | n/a | n/a | 36.78K | n/a | 7.07K | 612.96K | 193.5K |
| Selling & Marketing Expenses | n/a | 92.2M | 85.8M | 82.5M | 36.3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 797.57M | 623.75M | 512.76M | 367.4M | 253.76M | 154.07M | 162.27M | 103.09M | 118.59M | 105.91M | 31.56M | 29M | 19.52M |
| Income Tax | 473K | 636K | 6K | 5.63K | 13.51K | 1.6K | 1.6K | -1.06M | 1.07M | 1.6K | 1.6K | 18K | 32.92K |
| Shares Outstanding (Basic) | 103.13M | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.01M | 28.65M | 17.22M | 22.16M |
| Shares Outstanding (Diluted) | 103.13M | 95.88M | 94.05M | 81.25M | 70.36M | 55.19M | 54.71M | 46.18M | 43.24M | 36.07M | 28.65M | 17.26M | 22.16M |
| EPS (Basic) | -0.72 | -1.46 | -2.72 | -3.5 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EPS (Diluted) | -0.72 | -1.46 | -2.72 | -3.5 | -3.23 | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -0.75 |
| EBITDA | -116.72M | -158.85M | -262.97M | -285.15M | -230.7M | -153.53M | -161.9M | -102.63M | -115.13M | -104.65M | -30.66M | -26.21M | -16.32M |
| Depreciation & Amortization | n/a | 528K | 656K | 533.36K | 528.12K | 477.12K | 368.67K | 213.87K | 196.87K | 139.63K | 25.48K | 23.25K | 47.75K |